Credit Suisse Ag Theseus Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$4.69 - $8.36 $436 - $777	-93 Reduced 98.94%	1 $0
Q3 2022 Nov 10, 2022	BUY	$5.7 - $8.68 $456 - $694	80 Added 571.43%	94 $1,000
Q2 2022 Aug 12, 2022	BUY	$5.04 - $14.05 $70 - $196	14 New	14 $0

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.